No room for more mistakes at Lundbeck
Pharmaceutical company Lundbeck has a lot of work to do if it is to live up to its own long-term ambitions, analysts say. The company believes it can be done.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY CATHERINE BRETT
Lundbeck is treading water to avoid being overcome by falling share prices, high costs, low growth and a lack of earnings compared to others in the industry. Despite this, company leaders are optimistic and believe a golden era is coming over the next 6-8 years.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck introduces vaccine requirement for US staff
For subscribers
Covid-stricken US still causing Lundbeck problems
For subscribers
